Compare · MNPR vs NVO
MNPR vs NVO
Side-by-side comparison of Monopar Therapeutics Inc. (MNPR) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MNPR and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 360.3x MNPR ($481.9M).
- Over the past year, MNPR is down 9.7% and NVO is down 30.4% - MNPR leads by 20.7 points.
- MNPR has been more active in the news (6 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 15 for MNPR).
- Company
- Monopar Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $69.43-3.66%
- $38.82-1.05%
- Market cap
- $481.9M
- $173.66B
- 1M return
- -32.18%
- -10.14%
- 1Y return
- -9.67%
- -30.36%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 6
- 3
- Recent ratings
- 15
- 25
Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart, which is in Phase 2 clinical trial; and MNPR-101, a humanized monoclonal antibody for the treatment of advanced cancers and severe COVID-19 that is in preclinical stage. The company has a collaboration Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. It also has a collaboration agreement with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in multiple types of cancer. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MNPR
- SEC Form 4 filed by Monopar Therapeutics Inc.
- Chief Operating Officer Cittadine Andrew converted options into 4,384 shares and covered exercise/tax liability with 1,944 shares, increasing direct ownership by 4% to 58,054 units (SEC Form 4) to satisfy withholding tax
- Chief Executive Officer Robinson Chandler converted options into 9,801 shares and covered exercise/tax liability with 4,344 shares, increasing direct ownership by 5% to 104,724 units (SEC Form 4) to satisfy withholding obligation
- Chief Financial Officer Vu Quan Anh converted options into 614 shares and covered exercise/tax liability with 180 shares, increasing direct ownership by 20% to 2,655 units (SEC Form 4) (withholding obligation)
- SEC Form 144 filed by Monopar Therapeutics Inc.
- Chief Executive Officer Robinson Chandler exercised 29,056 shares at a strike of $21.74 and sold $2,556,851 worth of shares (29,056 units at $88.00) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: Director Tsuchimoto Kim R sold $455,567 worth of shares (4,090 units at $111.39) as part of a pre-agreed trading plan and exercised 4,090 shares at a strike of $22.04 (SEC Form 4)
- Amendment: Director Anderson Raymond exercised 3,142 shares at a strike of $30.00 and sold $351,835 worth of shares (3,142 units at $111.98) as part of a pre-agreed trading plan (SEC Form 4)
- Acting Chief Medical Officer Rioux Patrice exercised 1,380 shares at a strike of $0.01 and sold $111 worth of shares (1 units at $111.26) as part of a pre-agreed trading plan, increasing direct ownership by 37% to 5,065 units (SEC Form 4)
- Director Tsuchimoto Kim R sold $455,567 worth of shares (4,090 units at $111.39) as part of a pre-agreed trading plan, decreasing direct ownership by 36% to 7,396 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank